Press Releases

Beta Bionics, Inc., a medical technology company focused on the design, development, and commercialization of the iLet® bionic pancreas system, today announced the appointment of Christy Jones to its Board of Directors.

 

“We are delighted to welcome Christy to our Board of Directors,” commented Ed Damiano, President and Chief Executive Officer. “Christy is a highly respected entrepreneur with a successful track record of bringing new technologies to market. Her unique experience as a founder and CEO of both public and private companies in the health sciences and tech sectors, will be invaluable in guiding our mission to bring the iLet to as many people with diabetes as possible.”

Beta Bionics, Inc. today announced the appointment of Martha Goldberg Aronson as Chair of its Board of Directors, effective immediately.

Ms. Aronson, who joined the Beta Bionics Board as a Director in February of 2020, succeeds Ed Damiano, President and Chief Executive Officer of Beta Bionics, who has served as Chair since inception of the company in 2015. Dr. Damiano will remain a member of the Board while continuing to serve in his roles as President and Chief Executive Officer of Beta Bionics.

Beta Bionics Appoints Beth Brooke to Its Board as Independent Director

December 30, 2020

Beta Bionics, Inc. today announced that Beth Brooke has been appointed to the Company’s Board of Directors. "We are so pleased to have Beth join our Board of Directors at Beta Bionics. Her fierce commitment to egalitarianism, opportunity, diversity, and innovation is perfectly aligned with the core principles and values of our benefit mission at Beta Bionics,” - Ed Damiano, President and Chief Executive Officer of Beta Bionics.

Beta Bionics Appoints Martha Aronson and Sean Carney to Its Board As Independent Directors

February 20, 2020

Beta Bionics, Inc. today announced that Martha G. Aronson and Sean D. Carney have been appointed to the Company’s Board of Directors effective immediately. “We are all very excited and feel extremely fortunate, at Beta Bionics, to have Martha and Sean join our Board of Directors. Their experience and expertise in the commercial and financial aspects of our business are substantial, and will be invaluable assets to our Board and management team going forward,” said Ed Damiano, President and CEO of Beta Bionics. 

Beta Bionics, Inc. announced it has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its investigational iLet Bionic Pancreas System.

​Beta Bionics, Inc. announced that its bionic pancreas glucose control algorithms that use lifelong autonomous learning were deployed in a pilot study comparing usual care with automated insulin-only and bihormonal (insulin and glucagon) delivery in three patients with cystic fibrosis-related diabetes (CFRD).

​ConvaTec’s Unomedical subsidiary and Beta Bionics have entered into a collaboration and development agreement that will make portions of Unomedical’s world-class infusion sets available for use with the iLet Bionic Pancreas System.

​Beta Bionics, Inc. announced that the company has completed a $63 million Series B2 equity financing. This follows six months after the final close of another $63 million equity financing and brings the total combined Series B and B2 financings to just over $126 million.

Beta Bionics and Zealand Pharma announce superior glycemic control in Phase 2 home-use clinical trial testing the iLet® bionic pancreas using dasiglucagion.

First Home-Use Trial of the Bihormonal iLet With Dasiglucagon in a Pre-Filled, Commercial Ready, Pump Cartridge

May 22, 2019

​This home-use clinical trial is being conducted by Dr. Steven Russell and his clinical research team at the Massachusetts General Hospital.

​Beta Bionics announces that the company has now completed its Series B equity financing, which has reached a total of $63 million.  

Beta Bionics Awarded Up to $2 Million NIH Small Business Innovation Research (SBIR) Grant

October 9, 2018

Beta Bionics has been awarded up to $2 million in the form of an SBIR grant (R44-DK120234) by the NIDDK, which is part of the U.S. National Institutes of Health (NIH).

Beta Bionics has so far raised $50 million of a Series B equity financing.

The Beta Bionics iLet Bionic Pancreas System is now approved for clinical trials in adults with type 1 diabetes (T1D) using two highly accurate continuous glucose monitoring (CGM) systems: the Dexcom CGM and the Senseonics Eversense CGM

​Beta Bionics has received FDA approval to begin recruitment for home-use studies testing the insulin-only configuration of its iLet bionic pancreas system in adults and children with T1D.

Zealand Pharma boosts collaboration with Beta Bionics to advance development of its dasiglucagon in the iLet.

Zealand Pharma and Beta Bionics announce a positive outcome from the Phase 2a clinical safety trial using dasiglucagon in the dual-hormone artificial pancreas system, developed at Boston University and licensed to Beta Bionics. 

​The bionic pancreas system developed by Boston University (BU) investigators proved better than either conventional or sensor-augmented insulin pump therapy at managing blood sugar levels in patients with type 1 diabetes living at home, with no restrictions, over 11 days.

The bionic pancreas system developed by Boston University (BU) investigators proved better than either conventional or sensor-augmented insulin pump therapy at managing blood sugar levels in patients with type 1 diabetes living at home, with no restrictions, over 11 days.

Copenhagen, 13 December 2016 – Zealand Pharma (Zealand) today announced that it has dosed the first patients in its Phase IIa clinical trial with dasiglucagon1 in a dual-hormone artificial (or bionic) pancreas system from Beta Bionics.

Copenhagen, Denmark and Boston, Massachusetts, 10 June 2016 – Zealand Pharma, or Zealand, a peptide drug discovery, design and development company, and Beta Bionics, a medical technology company, jointly announced today that they have engaged in a collaboration.